secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001628280-24-046809
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab Q3 net product revenue rises 47% YoY to $101.8M; KarXT bridging study positive
--------------------------------------------------------------------------------

- Net product revenue $101.8M, up 47% YoY; net loss $41.7M ($0.42/ADS loss).
- VYVGART sales $27.3M (vs $4.9M YoY); ZEJULA $48.2M (+16%); NUZYRA $10.0M (+82%).
- KarXT bridging study in schizophrenia met primary endpoint (9.2-point PANSS reduction, p=0.0014); NDA submission expected early 2025.
- ZL-1310 (DLL3 ADC) Phase 1 data shows 74% ORR in extensive-stage SCLC; potential best-in-class.
- Cash position $716.1M; three product launches in China expected by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828024046809/0001628280-24-046809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828024046809/zlab-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-046809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer